View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 20, 2021

Gritstone, NIAID enter clinical trial agreement for next-gen Covid-19 vaccine

Gritstone has entered into a clinical trial agreement with the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to advance its Covid-19 programme, CORAL, for developing a second-generation vaccine.

Gritstone has entered into a clinical trial agreement with the US National Institutes of Health (NIH) unit the National Institute of Allergy and Infectious Diseases (NIAID) to advance its Covid-19 programme, CORAL, for developing a second-generation vaccine.

Gritstone noted that the vaccine can potentially provide prolonged protection, as well as potency against spike mutants of the virus.

A Phase I clinical trial, set to take place through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), is in development.

A grant from the Bill & Melinda Gates Foundation will back the preclinical analysis of the vaccine.

Gritstone co-founder, president and CEO Andrew Allen said: “Since inception, Gritstone has developed two core assets – cutting-edge T cell epitope identification and potent vaccines shown to activate a strong and broad immune response in humans – and both of these have been deployed in our quest for a second-generation SARS-CoV-2 vaccine.

“We are excited to be working with the experienced teams at NIAID and the IDCRC as well as the experts at the Gates Foundation and LJI [La Jolla Institute for Immunology] who have helped us design and pre-clinically test our novel vaccine concepts.”

The company can access validated SARS-CoV-2 epitopes through a license agreement with the LJI.

Using the epitopes identified by LJI and its EDGE and vaccine platform technologies, the company is developing a vaccine with spike and additional viral epitopes that offer good targets for T-cell immunity.

The company uses self-amplifying mRNA and adenoviral vectors to provide the SARS-CoV-2 viral antigens.

Gritstone chief scientific officer Karin Jooss said: “Our preclinical work has shown that our SARS-CoV-2 vaccines can induce sustained, high-titer neutralising antibodies and CD8+ T cell responses against the Spike protein, plus a broad CD8+ T-cell response against epitopes from multiple viral genes outside of Spike.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU